Sponsors of drug trials should publish clinical trial reports without redacting confidential information, the International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO) said in a statement last week.

The organizations said pharma companies should provide voluntary unrestricted access to clinical trial results data “within short timelines and without waiting for legal changes.”

ICMRA and the WHO also pressed the industry to provide wider access to clinical data for all new medicines and vaccines, regardless if they were given full approval, conditional approval, emergency-use approval or were rejected.

Read the joint statement here: https://bit.ly/3tnQqsl.